Mosliciguat

Roivant and its Pulmovant subsidiary reported a large, internally consistent randomized Phase II signal for once-daily inhaled mosliciguat in pulmonary hypertension associated with interstitial lung disease. At Week 16, pulmonary vascular resistance fell 56.3%…